Cannabis Law Report

SEPTEMBER 23, 2019

Due to the Schedule I classification by the Drug Enforcement Agency (DEA), researchers seeking to investigate health effects associated with cannabis must follow a regimented application process. 33 Unintentional exposures to marijuana in children have increased each year since 2012, likely due to legalization policies across the U.S.

Cannabinoids 40

Cannabinoids Marijuana Research and Development Access 40

Cannabis Law Report

JULY 12, 2019

This differs sharply from the conventional course of cannabis medicine, which is to use whole, clean plant extracts to treat epilepsy and to gradually discontinue use of conventional pharmaceuticals. An Israeli study of cannabis versus epilepsy, however, used natural extracts with a ratio of 20:1 CBD:THC. Lancet Neurol Dec 23 2015.

Extraction 73

Extraction Pharmaceutical CBD Epilepsy 73

The Cannigma

SEPTEMBER 12, 2021

Marijuana (defined in the US as any cannabis plant where THC>0.3%) is a schedule I drug according to the DEA and FDA. in 2008, 12% in 2012 and 15% in 2018. It has shown potential for a variety of conditions and symptoms such as obesity, diabetes, epilepsy, Parkinson’s disease, anxiety and osteoporosis. THC in 1993, 8.8%

THC 98

THC Research and Development Cannabinoids CBD 98